Literature DB >> 2611321

Testing whether an identified treatment is best.

E M Laska1, M J Meisner.   

Abstract

We consider the problem of testing whether an identified treatment is better than each of K treatments. Suppose there are univariate test statistics Si that contrast the identified treatment with treatment i for i = 1, 2,...., K. The min test is defined to be the alpha-level procedure that rejects the null hypothesis that the identified treatment is not best when, for all i, Si rejects the one-sided hypothesis, at the alpha-level, that the identified treatment is not better than the ith treatment. In the normal case where Si are t statistics the min test is the likelihood ratio test. For distributions satisfying mild regularity conditions, if attention is restricted to test statistics that are monotone nondecreasing functions of Si, then regardless of their covariance structure the min test is an optimal alpha-level test. Tables of the sample size needed to achieve power .5, .8, .90, and .95 are given for the min test when the Si are Student's t and Wilcoxon.

Entities:  

Mesh:

Year:  1989        PMID: 2611321

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  8 in total

Review 1.  Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.

Authors:  Toshimitsu Hamasaki; Scott R Evans; Koko Asakura
Journal:  J Biopharm Stat       Date:  2017-10-30       Impact factor: 1.051

2.  Generalized Confidence Intervals Compatible with the Min Test for Simultaneous Comparisons of One Subpopulation to Several Other Subpopulations.

Authors:  Julia N Soulakova
Journal:  Commun Stat Theory Methods       Date:  2017-06-07       Impact factor: 0.893

3.  The spectrum of neurobehavioral sequelae after repetitive mild traumatic brain injury: a novel mouse model of chronic traumatic encephalopathy.

Authors:  Anthony L Petraglia; Benjamin A Plog; Samantha Dayawansa; Michael Chen; Matthew L Dashnaw; Katarzyna Czerniecka; Corey T Walker; Tyler Viterise; Ollivier Hyrien; Jeffrey J Iliff; Rashid Deane; Maiken Nedergaard; Jason H Huang
Journal:  J Neurotrauma       Date:  2014-06-12       Impact factor: 5.269

4.  Assessing interactions for fixed-dose drug combinations in tumor xenograft studies.

Authors:  Jianrong Wu; Lorraine Tracey; Andrew M Davidoff
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

5.  Assessing interactions for fixed-dose drug combinations in subcutaneous tumor xenograft studies.

Authors:  Jianrong Wu
Journal:  Pharm Stat       Date:  2013-03-07       Impact factor: 1.894

6.  Verapamil SR and trandolapril combination therapy in hypertension--a clinical trial of factorial design. German Hypertension Study Group.

Authors:  J Scholze; P Zilles; D Compagnone
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

7.  Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.

Authors:  Xiaoyong Fu; Chad J Creighton; Nrusingh C Biswal; Vijetha Kumar; Martin Shea; Sabrina Herrera; Alejandro Contreras; Carolina Gutierrez; Tao Wang; Sarmistha Nanda; Mario Giuliano; Gladys Morrison; Agostina Nardone; Kristen L Karlin; Thomas F Westbrook; Laura M Heiser; Pavana Anur; Paul Spellman; Sylvie M Guichard; Paul D Smith; Barry R Davies; Teresa Klinowska; Adrian V Lee; Gordon B Mills; Mothaffar F Rimawi; Susan G Hilsenbeck; Joe W Gray; Amit Joshi; C Kent Osborne; Rachel Schiff
Journal:  Breast Cancer Res       Date:  2014-09-11       Impact factor: 6.466

8.  Testing multiple dose combinations in clinical trials.

Authors:  Saswati Saha; Werner Brannath; Björn Bornkamp
Journal:  Stat Methods Med Res       Date:  2019-09-24       Impact factor: 3.021

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.